Key Highlights

  • USD 120.71 was the Haemonetics (NYSE:HAE) price per published market data (October 16, 2026 intraday), 2.5% below the 52-week high of USD 123.77, own arithmetic. The 52-week low is USD 48.55 and market value is USD 5.49 billion.
  • 16% was the reported share price gain after a non-exclusive supply agreement with CSL Plasma, per published market data in the week of October 5. Terms were not disclosed in the releases reviewed. The stock is 12.2% above its September 17 close of USD 107.60, own arithmetic.
  • USD 339.4 million was first quarter fiscal 2027 revenue, up 5.6% and 5.9% organic, per the 8-K dated August 6, 2026. Adjusted EPS was USD 1.14, up 3.6%, with an adjusted operating margin of 23.4% and free cash flow of USD 39.1 million.
  • USD 140 is the new price target at Mizuho, raised from USD 95, with Barrington Research and BofA also at USD 140. That is 16.0% above the intraday price, own arithmetic, while the consensus target is USD 124.50, only 3.1% higher.

Price Action and Valuation Context

Haemonetics (NYSE:HAE) has risen 2.5 times from its 52-week low of USD 48.55, own arithmetic. Published market data show a trailing P/E of 58.73 against a forward P/E of 21.95, reflecting the gap between GAAP and adjusted earnings. The catalyst was the CSL Plasma agreement reported in the week of October 5. A supply agreement with a major collector can anchor disposables demand. Contract duration, volume and pricing were not disclosed in the filings reviewed through October 16, 2026.

Earnings and Guidance Drivers

Per the 8-K dated August 6, 2026, plasma revenue grew 8.2% organically, Blood Management Technologies grew 8.1%, and Interventional Technologies grew 2.8%. Other blood collection products fell 2.8%. Fiscal 2027 guidance rose to organic growth of 4% to 7% from 3% to 6%, and reported growth of 5% to 8% from 4% to 7%. Adjusted operating margin guidance of 50 to 100 basis points of expansion was unchanged. Total debt was USD 1,174.2 million and cash was USD 223.4 million at June 27, 2026, a net debt of USD 950.8 million, own arithmetic.

Analyst Positioning and Risks

Citi upgraded the shares to Buy with a USD 123 target in September, and Baird holds Outperform with a USD 119 target set on August 21. JPMorgan rates the shares Neutral with a USD 86 target from August 7, which is 28.8% below the intraday price, own arithmetic, and may be stale. Risks include dependence on plasma collectors, unconfirmed CSL Plasma economics, and a declining blood collection segment. The next results are due November 5, 2026.

Where Things Stand

Haemonetics (NYSE:HAE) sits 2.5% below its high because a reported CSL Plasma agreement and raised guidance arrived within weeks of each other, and analysts moved targets to USD 140. The fundamentals are steady: 5.9% organic growth, a 23.4% adjusted operating margin and raised fiscal 2027 growth guidance. The valuation has already moved, with the shares 12.2% above their September 17 close and the consensus target only 3.1% higher. Net debt of USD 950.8 million adds balance sheet risk. The next catalyst is fiscal second quarter earnings on November 5, 2026.